STOCK TITAN

Recursion (RXRX) Form 144: 100K Class A Shares Proposed Sale on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. (RXRX) Form 144 filed reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage Services with an approximate aggregate market value of $476,000, with an approximate sale date of 09/25/2025 on NASDAQ. The filing states the shares were originally acquired as Founders Shares on 09/01/2016 and were issued as compensation. The notice also discloses prior sales by related parties during the past three months totaling 817,875 Class A shares for gross proceeds of $3,386,380.00. The signer represents no undisclosed material adverse information exists and includes the standard attestation language required under Rule 144.

Positive

  • Disclosure compliance: The filer submitted a Form 144 specifying the proposed sale, broker, and sale date, satisfying Rule 144 notice requirements
  • Transaction history provided: The filing lists prior related sales in the past three months, offering transparency on recent insider dispositions

Negative

  • Significant insider liquidity: Related parties sold 817,875 Class A shares in the past three months for $3,386,380.00 in gross proceeds
  • Planned sale size: Proposed sale of 100,000 Class A shares (aggregate market value $476,000) could add to insider supply in the market

Insights

TL;DR: Insider-related sales reported; current filing seeks to sell 100,000 Class A shares for roughly $476K.

The Form 144 documents an intended controlled securities disposition under Rule 144, indicating the seller acquired the shares as founders' compensation in 2016. The filing lists multiple recent disposals by the same family/affiliated entities totaling 817,875 shares in the prior three months with combined gross proceeds of $3,386,380.00. This is a disclosure of planned and recent insider liquidity rather than an operational or earnings event. Materiality for investors depends on share count relative to total outstanding shares and any potential market impact from continued insider sales.

TL;DR: Form 144 compliance observed; filing includes standard attestation about material nonpublic information.

The document contains the required representations under Rule 144, including an attestation that the seller is not aware of undisclosed material adverse information. It identifies the nature of acquisition as founders' shares and states the transaction was compensation. The detailed listing of recent affiliated sales provides transparency about insider liquidity. The filing itself reflects routine compliance rather than new governance actions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the RXRX Form 144 report?

The Form 144 reports a proposed sale of 100,000 Class A shares via Fidelity on approximately 09/25/2025 with an aggregate market value of $476,000.

Who originally acquired the shares being sold?

The shares were acquired as Founders Shares on 09/01/2016 and were recorded as compensation.

How many shares were sold by related parties in the past three months?

Related parties sold 817,875 Class A shares in the past three months for gross proceeds of $3,386,380.00.

Where will the proposed sale be executed?

The filing indicates the sale is to be executed on NASDAQ through Fidelity Brokerage Services LLC.

Does the filer assert possession of undisclosed material information?

No; the signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

View RXRX Stock Overview

RXRX Rankings

RXRX Latest News

RXRX Latest SEC Filings

RXRX Stock Data

1.85B
506.92M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SALT LAKE CITY